AccuStem Sciences, Inc. ACUT
0.13 USD 0.00 (+0.00%)
At closeNov 9, 2026, 4:00 PM EST
0.13 Day range 0.13
0.117 52-week range 0.9979
- YTD
- -84.02%
- 1 year
- -85.56%
News
globenewswire.com AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP) PHOENIX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today…
globenewswire.com AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning PHOENIX, Ariz. and LONDON, Sept.
globenewswire.com AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as…
globenewswire.com AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as…
globenewswire.com AccuStem Sciences, Inc. Announces Chairman Purchase of Shares LONDON and PHOENIX, June 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced…
globenewswire.com AccuStem Sciences, Inc. Announces Chairman Purchase of Shares LONDON, June 13, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its…
globenewswire.com AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening LONDON and PHOENIX, Ariz., April 28, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk…
globenewswire.com AccuStem Sciences, Inc. Announces Chairman Purchase of Shares LONDON and PHOENIX, Ariz., April 21, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer,…
globenewswire.com AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan LONDON and PHOENIX, April 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of…
globenewswire.com AccuStem Sciences, Inc. Announces Chairman Purchase of Shares LONDON and PHOENIX, April 10, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced…
globenewswire.com AccuStem Sciences, Inc. Announces Chairman Purchase of Shares LONDON and PHOENIX, April 08, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced…
globenewswire.com AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States LONDON and PHOENIX, April 04, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of…
globenewswire.com AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test AccuStem pursuing strategic commercialization plan intending to launch the MSC test in the US in 2026 LONDON and PHOENIX, Ariz., March 18, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:…
globenewswire.com AccuStem Sciences, Inc. Announces Chairman Purchase of Shares LONDON and PHOENIX, Jan. 03, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced…
globenewswire.com AccuStem Sciences, Inc. and EmeritusDX Announce Joint Product Development Agreement and Strategic Partnership LONDON and PHOENIX, July 17, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, and…
globenewswire.com AccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer LONDON and PHOENIX, July 11, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, signs…